Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Durvalumab - Celgene/MedImmune

Drug Profile

Durvalumab - Celgene/MedImmune

Alternative Names: Anti-PD-L1 monoclonal antibody; Anti-PD-LI mAb; Anti-programmed cell death 1 ligand 1 monoclonal antibody; Imfimzi; Imfinzi; MEDI-4736

Latest Information Update: 14 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer Advaxis; AIO Studien gGmbH; AstraZeneca; AVEO Oncology; Big Ten Cancer Research Consortium; Biocompatibles International; Canadian Cancer Trials Group; Cancer Research UK; Case Comprehensive Cancer Center; Celgene International SARL; Centre hospitalier de l'Universite de Montreal; Centre Leon Berard; Charite - Universitatsmedizin Berlin; Childrens Hospital Los Angeles; Eli Lilly and Company; Fondazione IRCCS Istituto Nazionale dei Tumori; GlaxoSmithKline; Gradalis; Grand Hopital de Charleroi; Grupo Espanol de Tumores Neuroendocrinos; Gustave Roussy; Immunocore; Innate Pharma; Institut Claudius Regaud; Jules Bordet Institute; Juno Therapeutics; Kyoto Breast Cancer Research Network; Ludwig Institute for Cancer Research; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; Mirati Therapeutics; Myriad Genetic Laboratories; National Cancer Institute (USA); National Health and Medical Research Council; NHS Greater Glasgow and Clyde; Northwestern University; Pharmacyclics; Plexxikon; Radboud University; Samsung Medical Center; Spanish Oncology Genito-Urinary Group; Swiss Group for Clinical Cancer Research; UNC Lineberger Comprehensive Cancer Center; UNICANCER; University College London; University Health Network; University of Colorado at Denver; University of Kansas Medical Center; University of Maryland Greenbaum Cancer Center; University of Southern California; University of Sydney; University of Texas M. D. Anderson Cancer Center; VentiRx Pharmaceuticals; Washington University School of Medicine; Yale University; Yonsei University College of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Small cell lung cancer
  • Registered Urogenital cancer
  • Phase III Biliary cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours
  • Phase II/III Pancreatic cancer
  • Phase II Acute myeloid leukaemia; Brain metastases; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Gallbladder cancer; Germ cell and embryonal neoplasms; Glioblastoma; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Oropharyngeal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Uterine cancer
  • Phase I/II Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Haematological malignancies; Lung cancer; Lymphoma; Malignant melanoma; Peripheral T-cell lymphoma; Renal cancer
  • Phase I Gastrointestinal cancer; Vulvovaginal cancer
  • No development reported CNS cancer; Lymphoproliferative disorders; Thyroid cancer

Most Recent Events

  • 14 Sep 2021 Celegen Corporation completes a phase I/II trial (Combination therapy, Recurrent, Second-line therapy or greater) in platinum-resistant Ovarian cancer
  • 09 Sep 2021 Updated efficacy and adverse events data from phase III POSEIDON trial in Non-small cell lung cancer released by AstraZeneca
  • 30 Aug 2021 University of Cincinnati plans a phase II trial for Liver cancer (Combination therapy, First-line therapy) (IV) in October 2021 (NCT05027425)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top